Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO 2019. In this first video, the doctors discuss “Stage I NSCLC – Should Retrospective Japanese Data Lead Us to Lower Our Threshold for Recommending Adjuvant Chemotherapy”. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Author: Editor
Mohammad Jahanzeb, MD shares data presented at WCLC 2019 that he found interesting.
Mohammed Jahanzeb, MD describes what he would like to see next in NSCLC research.
Nearly 14,000 women will die from ovarian cancer in 2019. Now, new research has found that women who use IUDs for birth control may be lowering their ovarian cancer risk. For five years, Amy Dickson Plache has bravely battled ovarian cancer with chemotherapy, clinical trials, radiation and more. Even now, she’s in treatment. “I won’t be cured, but I’ll just live with this as a chronic disease much like you know someone who had diabetes or you know arthritis,†she said. Plache has an inherited genetic mutation known to increase the risk of ovarian cancer. Tests show her daughter Abby…
Mohammed Jahanzeb, MD explains the design of the study examining real-world treatment patterns and outcomes in U.S. ALK+ NSCLC patients receiving immuno-oncology therapy.
Mohammed Jahanzeb, MD on how this data will affect clinicians today.
Mohammed Jahanzeb, MD answers questions asked by his colleagues.
– Results from ENTRATA Phase 2 trial of telaglenastat in patients with advanced renal cell carcinoma (RCC) accepted as Late-Breaking Oral Presentation  – Data from INCB001158 clinical program accepted as Oral Presentation  SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 – Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that new data from two oncology programs have been selected for oral presentations at the European Society for Medical Oncology (ESMO) 2019 Congress to be held September 27-October 1,…
First Phase 3 Study Combining KYPROLIS and DARZALEX, Two Critical Mechanisms of Action in Treatment of Multiple Myeloma  THOUSAND OAKS, Calif. (Sept. 13, 2019) — Amgen (NASDAQ:AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) (KdD) compared to KYPROLIS and dexamethasone alone (Kd) met its primary endpoint of progression-free survival (PFS). The regimen resulted in a 37% reduction in the risk of progression or death in patients with relapsed or refractory multiple myeloma treated with KdD (HR=0.630; 95% CI: 0.464, 0.854; p=0.0014). The median PFS for patients treated with Kd alone was 15.8 months, while the median…
Shauna Campbell, MD of Cleveland Clinic shares three nomograms that were presented on salvage radiotherapy. _____ The integration of prostate-specific antigen (PSA) kinetics into a nomogram widely used to predict outcomes of salvage therapy offers physicians and patients a more nuanced, longer-term look at prostate cancer-specific outcomes. In 2007, a multi-institutional cohort led by Cleveland Clinic’s Glickman Urological and Kidney Institute developed a nomogram to predict prostate cancer-specific and all-cause mortality at six years after salvage radiotherapy (SRT). Almost a decade later, a study led by Cleveland Clinic Cancer Center radiation oncologist Rahul D. Tendulkar, MD, updated the nomogram with evidence that early initiation of…
- DKN-01 Monotherapy Patient with an Ongoing Complete Response - Enhanced PFS in patients with Wnt Activating Mutations and DKK1-high Tumors CAMBRIDGE, Mass., Sept. 17, 2019 /PRNewswire/ – Leap Therapeutics, Inc. (Nasdaq: LPTX) today announced an oral and poster presentation of updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, its anti-Dickkopf-1 (DKK1) antibody, as both a monotherapy and in combination with paclitaxel chemotherapy in patients with advanced gynecological malignancies will be presented at the 2019 International Gynecologic Cancer Society Annual Global Meeting taking place September 19-21, 2019 in Rio de Janeiro, Brazil. The poster will be presented on Friday, September 20…
New research adds to accumulating evidence of benefit for patients treated at high-volume facilities or by high-volume providers. PLYMOUTH MEETING, PA [September 17, 2019] — New research in the September 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that providers with more experience treating people with multiple myeloma have better outcomes than those with more limited experience. In general, providers who saw the most cases were more likely to be located at academic, NCI-designated cancer centers. However, the researchers found that the very highest-volume providers at community facilities did achieve equally low mortality rates as clinicians at NCI-designated cancer centers.…
Roswell Park researchers present findings at ASTRO Annual Meeting Aspirin improved overall survival for patients with head/neck, lung cancers Patients in both studies also received radiation or chemoradiation therapy Future studies will help determine which patients benefit most  BUFFALO, N.Y. — What if a drug that sits in nearly everyone’s medicine cabinet could help extend the lives of some cancer patients? In companion presentations at the American Society for Therapeutic Radiation Oncology (ASTRO) Annual Meeting in Chicago, doctors from Roswell Park Comprehensive Cancer Center report new evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients undergoing treatment…
Shauna Campbell, MD of Cleveland Clinic answers a question received from colleagues: how does it differ from previously published nomograms? _______ The integration of prostate-specific antigen (PSA) kinetics into a nomogram widely used to predict outcomes of salvage therapy offers physicians and patients a more nuanced, longer-term look at prostate cancer-specific outcomes. In 2007, a multi-institutional cohort led by Cleveland Clinic’s Glickman Urological and Kidney Institute developed a nomogram to predict prostate cancer-specific and all-cause mortality at six years after salvage radiotherapy (SRT). Almost a decade later, a study led by Cleveland Clinic Cancer Center radiation oncologist Rahul D. Tendulkar, MD, updated the nomogram with…
Shauna Campbell, MD of Cleveland Clinic explains the impact of post-prostatectomy prostate specific antigen (PSA) kinetics on outcomes of salvage radiotherapy. _______ The integration of prostate-specific antigen (PSA) kinetics into a nomogram widely used to predict outcomes of salvage therapy offers physicians and patients a more nuanced, longer-term look at prostate cancer-specific outcomes. In 2007, a multi-institutional cohort led by Cleveland Clinic’s Glickman Urological and Kidney Institute developed a nomogram to predict prostate cancer-specific and all-cause mortality at six years after salvage radiotherapy (SRT). Almost a decade later, a study led by Cleveland Clinic Cancer Center radiation oncologist Rahul D. Tendulkar, MD, updated the nomogram…
New discovery opens new potentially effective approaches to utilize checkpoint inhibitors for treatment of pancreatic cancer and other types of cancers that are unresponsive to current immunotherapies. HOUSTON, Sept. 16, 2019 - Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its sponsored research at MD Anderson Cancer Center has resulted in the filing of a new patent on behalf of MD Anderson Cancer Center covering the combination of its immune-stimulating/transcriptional-modulator, WP1066, with well-known immune checkpoint inhibitors. Read press release online: https://www.prnewswire.com/news-releases/moleculin-announces-its-sponsored-research-at-md-anderson-cancer-center-has-resulted-in-the-filing-of-patent-protection-for-new-discovery-300918401.html “We had previously announced preliminary preclinical data…
Dr. Mohammed Jahanzeb, MD explains the health-related quality of life data from the ALTA-1L trial.
Dr. Mohammed Jahanzeb, MD provides Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs. Crizotinib in NSCLC (ALTA-1L).
Dr. Erin Murphy, MD of Cleveland Clinic provides insight on how this will affect clinicians today. _____ Preoperative (neoadjuvant) stereotactic radiosurgery (SRS) with dose escalation followed by surgical resection for brain metastases > 2 cm yielded local control comparable to that with postoperative SRS or whole-brain radiation therapy (WBRT) — with the benefits of acceptable acute toxicity and a low incidence of leptomeningeal disease. These preliminary findings from a Cleveland Clinic prospective phase 1/2 clinical trial were presented Sept. 15 at the 2019 annual meeting of the American Society for Radiation Oncology (ASTRO). “So far we have seen excellent results…
Dr. Erin Murphy, MD of Cleveland Clinic answers a question received form colleagues: why dose escalation? _____ Preoperative (neoadjuvant) stereotactic radiosurgery (SRS) with dose escalation followed by surgical resection for brain metastases > 2 cm yielded local control comparable to that with postoperative SRS or whole-brain radiation therapy (WBRT) — with the benefits of acceptable acute toxicity and a low incidence of leptomeningeal disease. These preliminary findings from a Cleveland Clinic prospective phase 1/2 clinical trial were presented Sept. 15 at the 2019 annual meeting of the American Society for Radiation Oncology (ASTRO). “So far we have seen excellent results…
Dr. Erin Murphy, MD of Cleveland Clinic explains the phase I dose escalation study for neoadjuvant radiosurgery for large brain metastases. _____ Preoperative (neoadjuvant) stereotactic radiosurgery (SRS) with dose escalation followed by surgical resection for brain metastases > 2 cm yielded local control comparable to that with postoperative SRS or whole-brain radiation therapy (WBRT) — with the benefits of acceptable acute toxicity and a low incidence of leptomeningeal disease. These preliminary findings from a Cleveland Clinic prospective phase 1/2 clinical trial were presented Sept. 15 at the 2019 annual meeting of the American Society for Radiation Oncology (ASTRO). “So far…
Philadelphia, PA (September 16, 2019) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates National Childhood Cancer Awareness Month this September and reiterates its support for children and all those affected by childhood cancer. Cancer remains one of the greatest current health challenges, and childhood cancer kills more children in the United States than any other disease. “In commemorating this month, we recognize not only the children currently battling cancer, but also the families of those children, the clinicians and caregivers treating them, the survivors, the children who have lost their lives, and the researchers working to defeat this disease, 
State-of-the-art AI algorithms applied to digitised images of oral cancer tissue specimens can be used to predict their chances of survival by measuring the abundance of Tumour infiltrating immune cells Tumour infiltrating lymphocytes (a specific type of immune cells) are key in determining how oral cancers spread and react to treatments University of Warwick researchers were able to look at immune cells that have infiltrated into the tumour with an accuracy of over 96% and stratify patients into low-risk and high-risk in terms of their disease free survival. The chances of surviving oral cancers can be predicted by state of…
– Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 –  BOTHELL, Wash. and TOKYO, September 16, 2019 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellasâ€) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin and granted Priority Review for the treatment of patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. The filing is based…
      Phase 2 GRIFFIN study presented at 17th IMW meeting is the fourth randomized study to investigate the clinical benefit of DARZALEX® in the frontline setting ·         New results from Phase 2 PLEIADES study evaluating a DARZALEX® subcutaneous formulation also presented  BOSTON, September 15, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized Phase 2 GRIFFIN (MMY2004) study showing that the addition of DARZALEX® (daratumumab) to bortezomib, lenalidomide and dexamethasone (VRd) induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation (ASCT) compared with…
Austin, Texas – September 16, 2019 – The iQ Group Global, an enterprise dedicated to developing early stage bioscience assets, today announced it has added a novel anticancer drug platform to its portfolio that has the ability to develop a range of cancer therapeutics. TEX-Core is an anticancer drug platform that has the ability to develop a range of well-tolerated, MRI-detectable cancer therapeutics that target drug-sensitive and drug-resistant solid tumors. The first cancer therapeutic to be commercialized from the platform is OxaliTEX, a novel chemical entity (WO 2015/191797) that targets only solid tumor cells, activates within the tumor and overcomes drug-resistance…
he Tisch Cancer Institute Deepens Bladder Cancer Care With New Center of Excellence  (New York – September 12, 2019) The Icahn School of Medicine at Mount Sinai has been awarded nearly $1.7 million in grant funding from the U.S. Department of Defense to study how bladder cancer affects certain types of white blood cells called “natural killer†cells, or NK cells, which control and limit tumor growth. A clinical and research team of investigators with expertise in bladder cancer and immunotherapy will also design interventions to reverse NK cell dysfunction. According to the U.S. Department of Veterans Affairs, bladder cancer…
National Comprehensive Cancer Network hosts summit on defining, measuring, and applying quality in an evolving health policy landscape and the implications for cancer care. #NCCNPolicy WASHINGTON, D.C. [September 12, 2019] — The National Comprehensive Cancer Network® (NCCN®) hosted a policy summit at the National Press Club in Washington, DC, today, addressing how to define, measure, and apply quality in cancer care. Speakers across the cancer care continuum shared perspectives on current quality measurement initiatives including the Oncology Care Model and the Merit-based Incentive Payment System (MIPS), and looked ahead to future trends in this area. “A lot of effort has already gone toward measuring quality…
Philadelphia, PA (September 10, 2019) – Oncoceutics, Inc. announced a scientific publication in the Journal of Neuro-Oncology describing a complete response and other forms of clinical benefit in pediatric and adult H3 K27M-mutant glioma patients treated with ONC201 on expanded access protocols. This manuscript details radiographic findings and other clinical outcomes in eighteen H3 K27M-mutant glioma patients who were enrolled on expanded access protocols. These patients initiated ONC201 after prior radiation, and in many cases after also failing additional chemotherapy, a disease setting in neuro-oncology where no available therapies have been proven effective. Overall findings include disease stabilization and radiographic regressions after…
– 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm – – Company Plans to Discuss Updated Results with FDA – – AVEO to Host Conference Call Today at 8:00 am Eastern Time – CAMBRIDGE, Mass. – September 10, 2019 – AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. TIVO-3 is the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA®) to sorafenib in 350 subjects with highly refractory metastatic renal cell carcinoma (RCC). These results include an OS hazard ratio…
Program includes debate and interactive case studies on emerging cancer care practices. #NCCNhem19. SAN FRANCISCO, CA [September 10, 2019] — World-renowned experts on blood cancers are meeting in San Francisco on September 27-28, to help clinicians stay up-to-date on new, practice-changing strategies to manage patients with hematologic malignancies, at the NCCN 2019 Annual Congress: Hematologic Malignanciesâ„¢, presented by the National Comprehensive Cancer Network® (NCCN®), and co-chaired by Ranjana H. Advani, MD, Saul Rosenberg Professor of Lymphoma, Stanford University School of Medicine and Andrew D. Zelenetz, MD, PhD, Medical Director, Quality Informatics, Memorial Sloan Kettering Cancer Center. The Congress will address new, emerging, and novel therapeutic agents, diagnostics, and other advances in…
Dr. Neal provides insight on the horizon for the upcoming year.
Dr. Neal explains the unmet needs for this patient population.
In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone AstraZeneca today presented detailed results from the Phase III CASPIAN trial, showing IMFINZI® (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC). IMFINZI in combination with four cycles of standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) demonstrated a statistically-significant and clinically-meaningful improvement in OS vs. SoC chemotherapy consisting of up to six cycles of chemotherapy and optional prophylactic cranial irradiation (PCI). The risk of death was reduced by 27% (equal to…
Phase One Study Shows Novel KRAS Inhibitor Well Tolerated by Patients with Adenocarcinoma and Non-Small Cell Lung Cancer Barcelona–Sunday, September 8 at 9:45 a.m. CEST — A clinical trial testing the toxicity of a KRAS inhibitor demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation, according to Ramaswamy Govindan, M.D., from the Siteman Cancer Center at Washington University School of Medicine, St. Louis. The KRAS G12C mutation is found in approximately 14 percent of patients with lung adenocarcinoma and 11 percent of patients with non-small cell lung…
(9 September, Tokyo) In a recent study published in the journal Haematologica, researchers at Juntendo University used stem cell technology to produce immune cells with an enhanced ability to fight aggressive tumors of the nasal cavity. A lesser known but invasive form of cancer prevalent in Asian countries is extranodal natural killer/T cell lymphoma (ENKL). While it starts within the nasal cavity it often spreads to the digestive system, kidneys and bone marrow. At present, the enzymeL-asparaginase is the only therapy available for treating ENKL. However, many patients do not respond well to L-asparaginase thereby greatly decreasing their chances of prolonged survival. Now,…
Phase 3 Data for KEYTRUDA® (pembrolizumab) as Neoadjuvant Therapy in Combination with Chemotherapy in Patients with Triple-Negative Breast Cancer (KEYNOTE-522) to be Featured in ESMO Presidential Symposium and Official Press Program Data for LYNPARZA Included in ESMO Presidential Symposium and Official Press Program: in Metastatic Castration-Resistant Prostate Cancer (PROfound) and in Advanced Ovarian Cancer (PAOLA-1) Monday, September 9, 2019 6:45 am EDT KENILWORTH, N.J.–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from its broad oncology portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain,…
54% of 13 Evaluable Non-Small Cell Lung Cancer Patients Experienced a Partial Response at the Target Dose of 960 mg in the  Ongoing Phase 1 Study  46% of Patients had Stable Disease for a Disease Control Rate of  100% at the Target Dose  FDA Grants AMG 510 Fast Track Designation for Previously Treated  Metastatic NSCLC With KRAS G12C Mutation  THOUSAND OAKS, Calif. (Sept. 8, 2019) — Amgen (NASDAQ:AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. AMG 510 is a…
Dr. Neal provides the most commonly asked questions from colleagues and the recent findings in NSCLC.
Dr. Neal describes TAK-788’s safety profile and the side effects that come along with the drug’s use.
Dr. Neal provides details on TAK-788 Phase 1/2 study.
Dr. Neal explains what EGFR exon 20-mutant NSCLC is and how many patients have this particular mutation.
TORONTO, ON and LONDON, UK / ACCESSWIRE / September 6, 2019 / Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company discovering and developing first-in-class targeted cancer therapeutics, today announced that it has entered into a strategic alliance with Image Analysis Group (“IAGâ€), a UK-based company with unique expertise in medical imaging and artificial intelligence (“AIâ€)-based image analytics, whereby the companies will join their efforts in the development of Soricimed’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel. The partners will validate the use of advanced image assessment and AI-derived markers to predict patient treatment response in…
FINDINGS Breast cancer surgeons performing lumpectomies seek to spare healthy breast tissue while removing all cancerous cells, but determining appropriate margins and avoiding follow-up surgeries are ongoing challenges. This retrospective, single-institution review found that intraoperative teamwork between a breast cancer surgeon and a dedicated breast pathologist – utilizing tissue-marking ink and gross examination with magnification to evaluate margins – is an accurate, rapid and cost-effective means of significantly reducing the need for second-surgery margin re-excisions or mastectomies.  BACKGROUND Several studies have shown significantly increased local breast cancer recurrence rates in patients with low-stage breast carcinoma in whom margins were…
Hamburg, Germany and Baltimore, Maryland, 2019.09.04 ̶ Using Sysmex Inostics’ novel SafeSEQ next- generation sequencing cell-free DNA technology, investigators from the Biomedical Research Institute of Malaga [(IBIMA)-CIMES-UMA, Malaga Spain] and collaborators have published the first pilot study to examine the use of a non-invasive liquid biopsy in early diagnosis of breast cancer. This study was unique in that the ctDNA analyses was performed before any invasive diagnostic procedure or treatment. The SafeSEQ liquid biopsy technology has shown sensitivity down to five mutant molecules in a background of ten thousand normal ones (or 0.05% mutant allele frequency also known as MAF).…
Yes. Screening techniques for ovarian cancer are nonexistent. Studies have looked at combinations of blood markers and ultrasounds, but they did not show a survival improvement. Ultimately, if a patient undergoes screening, it should lead to some improvement in outcome or prevention of the cancer altogether. John M. NakayamaAI can help us in this area because cancer results from a combination of genetic and environmental factors. We can try to account for more factors using AI, such as other genetic markers, epigenetic markers, changes in lipids, earlier CT or ultrasound findings that could be predictive. Putting those together would generate…
(Reuters Health) – Cancer specialists only rarely advise patients on lifestyle changes that could improve overall health and possibly also reduce the risk of recurrence, a new survey suggests. The survey of doctors from a Midwestern health system found that oncologists were far less likely than primary care physicians to offer advice on health promotion strategies, such as weight loss and smoking cessation, researchers reported in the journal Cancer. With oncologists reticent to offer advice on lifestyle changes, the onus may fall upon patients to bring the topic up and to find ways on their own to address changes, said…
– Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients;(1) EVALUATE-HF results complement findings(2) - PROVE-HF establishes significant correlation between improvement in widely used cardiac biomarker and positive changes in heart structure and ability to pump blood in patients taking Entresto(1) – Safety and tolerability of Entresto were comparable to previously reported findings(1,2,3) EAST HANOVER, N.J., Sept. 2, 2019 /PRNewswire/ – Novartis announced today results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of Entresto® (sacubitril/valsartan) in…
(New York, NY – September 3, 2019) – September is Thyroid Cancer Awareness Month,and doctors in the Mount Sinai Health System are promoting early detection by encouraging high-risk groups to be aware of symptoms. “While the overall prognosis for the majority of thyroid cancers is excellent, early diagnosis and treatment are critical to improve survival and decrease the risk of future recurrence. In addition, in many cases, early diagnosis and appropriate surgical management often obviates the need for additional therapies such as radiation or chemotherapy,†says Brett Miles, MD, DDS, Professor and Co-Chief of the Division of Head and Neck Oncology…